Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Actinogen Medical ( (AU:ACW) ) has shared an announcement.
Actinogen Medical has received a $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending approval. This funding is crucial as the company progresses towards key milestones in its Alzheimer’s phase 2b/3 clinical trial, with interim results expected in January 2026 and final results in Q4 2026. The rebate supports Actinogen’s financial strategy and underscores its commitment to advancing its clinical trials, potentially strengthening its position in the biotechnology industry.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a promising treatment for Alzheimer’s Disease, Depression, and potentially other conditions like Fragile X Syndrome. The company aims to address the substantial unmet medical need for improved treatments in these areas.
Average Trading Volume: 2,554,642
Technical Sentiment Signal: Hold
Current Market Cap: A$98.44M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.